Dr. Limonadi’s FDA-cleared Neurosplint is designed to revolutionize treatment for mild to moderate Carpal Tunnel Syndrome (CTS). CTS is the second leading cause of disability in the US with overall prevalence of 3.0-5.8% among women and 0.6-2.1% among men in the general population1,2, yet no significant innovation has occurred in conservative treatment measures for decades.
The standard of care for mild to moderate CTS is to splint the wrist during nighttime only. However, this widely practiced standard fails to address many contributing activities. Repetitive manual work tasks involving flexion and extension at the wrist, which causes compression of median nerve have been shown to damage the median nerve and cause CTS3. Three studies have pointed to wrist flexion or extension for at least half of the working day as carrying a significantly high risk. In one study risks were elevated 5-8-fold when the self-reported time spent in activities with the wrist flexed or extended was ≥20 hours/week4, and in a second the overall risk for CTS was 2.1 to 2.7 for those estimating that they bent or twisted their wrists for >3.5 hours per day vs. 0 hours/day5.
In order to maintain the traditional standard of care while additionally addressing these activity-based factors, the Neurosplint functions as both a rigid night splint and a daytime ergonomic feedback device. When practical, the device worn with rigid inserts as a stereotypical brace allows the user to immobilize her/his wrist while asleep or resting. However, with the rigid inserts removed during activities, the device employs a microprocessor-enabled positional monitoring mechanism to protect users from extreme degrees of flexion and extension using sensory feedback to encourage behavioral modification. In addition Neurosplint’s mobile and web software suite empowers individuals, care providers and even ergonomic assessors in risk prone industries to evaluate behavioral history and track improvement trends.
1. de Krom MCTFM, Kester ADN, Knipschild PG: Carpal tunnel syndrome: prevalence in the general population. J Clin Epidemiol
1992; 45: 373–6.
2. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosen I: Prevalence of carpal tunnel syndrome in a general population. JAMA 1999, 282:153-158.
3. Klaus Gierseipen, Michael Spallek, Carpal Tunnel Syndrome as an occupational disease. Deutshes Arzteblatt International. 2011; 108(14): 238-42.
4. de Krom MC, Kester AD, Knipschild PG, Spaans F. Risk factors for carpal tunnel syndrome. American Journal of Epidemiology. 1990;132:1102–1110.
5. Nordstrom DL, Vierkant RA, Layde PM, Smith MJ. Comparison of self-reported and expert-observed physical activities at work in a general population. Am J Ind Med. 1998;34:29–35.